(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.
The three biggest winners today are Zai Lab, ImmunoGen, and Cenovus Energy.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | Zai Lab (ZLAB) | 41.50 | 2.77% | 2023-03-02 06:10:37 |
| 2 | ImmunoGen (IMGN) | 4.13 | 2.74% | 2023-03-02 07:28:24 |
| 3 | Cenovus Energy (CVE) | 19.00 | 2.1% | 2023-03-02 04:12:50 |
| 4 | POSCO (PKX) | 63.85 | 2.03% | 2023-03-02 07:27:02 |
| 5 | MicroVision (MVIS) | 2.40 | 1.69% | 2023-03-02 07:29:33 |
| 6 | Gevo (GEVO) | 1.87 | 1.63% | 2023-03-02 07:27:33 |
| 7 | Toronto Dominion Bank (TD) | 67.32 | 1.05% | 2023-03-02 07:28:22 |
| 8 | Flex (FLEX) | 22.98 | 0.92% | 2023-03-02 04:12:04 |
| 9 | Inovio Pharmaceuticals (INO) | 1.25 | 0.81% | 2023-03-02 07:28:27 |
| 10 | Tyson Foods (TSN) | 59.64 | 0.59% | 2023-03-02 06:42:49 |
The three biggest losers today are VerifyMe, Plug Power, and Credit Suisse Group.
| Rank | Financial Asset | Price | Premarket Change |
Updated (EST) |
|---|---|---|---|---|
| 1 | VerifyMe (VRME) | 1.65 | -4.62% | 2023-03-02 04:09:23 |
| 2 | Plug Power (PLUG) | 13.76 | -3.17% | 2023-03-02 07:30:12 |
| 3 | Credit Suisse Group (CS) | 2.91 | -3% | 2023-03-02 07:23:17 |
| 4 | Shinhan Financial Group (SHG) | 29.01 | -2.45% | 2023-03-02 07:20:10 |
| 5 | Banco Santander Brasil (BSBR) | 5.32 | -2.03% | 2023-03-02 04:11:39 |
| 6 | Lloyds Banking Group (LYG) | 2.45 | -2% | 2023-03-02 07:16:48 |
| 7 | Xenetic Biosciences (XBIO) | 0.50 | -1.96% | 2023-03-02 04:21:13 |
| 8 | Prudential Public Limited Company (PUK) | 30.51 | -1.8% | 2023-03-02 07:19:21 |
| 9 | Merrimack Pharmaceuticals (MACK) | 11.51 | -1.79% | 2023-03-02 04:13:55 |
| 10 | DouYu (DOYU) | 1.26 | -1.56% | 2023-03-02 06:17:40 |
Premarket Winners today
1. Zai Lab (ZLAB) – Premarket: 2.77%
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
NASDAQ ended the session with Zai Lab jumping 8.68% to $40.38 on Thursday, after two consecutive sessions in a row of gains. NASDAQ fell 0.66% to $11,379.48, after four successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Zai Lab’s stock is considered to be oversold (<=20).
Volatility
Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.99%, a negative 0.42%, and a positive 3.96%.
Zai Lab’s highest amplitude of average volatility was 4.18% (last week), 3.19% (last month), and 3.96% (last quarter).
Yearly Top and Bottom Value
Zai Lab’s stock is valued at $40.38 at 07:34 EST, way below its 52-week high of $56.06 and way higher than its 52-week low of $20.98.
Moving Average
Zai Lab’s worth is higher than its 50-day moving average of $38.53 and way higher than its 200-day moving average of $36.70.
More news about Zai Lab.
2. ImmunoGen (IMGN) – Premarket: 2.74%
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
NASDAQ ended the session with ImmunoGen jumping 3.61% to $4.02 on Thursday while NASDAQ dropped 0.66% to $11,379.48.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.252.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -157.66%.
Yearly Top and Bottom Value
ImmunoGen’s stock is valued at $4.02 at 07:34 EST, way under its 52-week high of $6.63 and way above its 52-week low of $3.10.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ImmunoGen’s stock is considered to be oversold (<=20).
Volatility
ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.29%, a negative 1.61%, and a positive 2.91%.
ImmunoGen’s highest amplitude of average volatility was 3.35% (last week), 3.23% (last month), and 2.91% (last quarter).
More news about ImmunoGen.
3. Cenovus Energy (CVE) – Premarket: 2.1%
Cenovus Energy Inc., together with its subsidiaries, develops, produces, and markets crude oil, natural gas liquids, and natural gas in Canada, the United States, and the Asia Pacific region. The company operates through Oil Sands, Conventional, Offshore, Canadian Manufacturing, U.S. Manufacturing, and Retail segments. The Oil Sands segment develops and produces bitumen and heavy oil in northern Alberta and Saskatchewan. This segments Foster Creek, Christina Lake, Sunrise, and Tucker oil sands projects, as well as Lloydminster thermal and conventional heavy oil assets The Conventional segment holds assets primarily located in Elmworth-Wapiti, Kaybob-Edson, Clearwater, and Rainbow Lake operating in Alberta and British Columbia, as well as interests in various natural gas processing facilities. The offshore segment engages in the exploration and development activities. The Canadian Manufacturing segment includes the owned and operated Lloydminster upgrading and asphalt refining complex, which upgrades heavy oil and bitumen into synthetic crude oil, diesel fuel, asphalt, and other ancillary products, as well as owns and operates the Bruderheim crude-by-rail terminal and two ethanol plants. The U.S. Manufacturing segment comprises the refining of crude oil to produce diesel, gasoline, jet fuel, asphalt, and other products. The Retail segment consists of marketing of its own and third-party refined petroleum products through retail, commercial, and bulk petroleum outlets, as well as wholesale channels. Cenovus Energy Inc. was founded in 2009 and is headquartered in Calgary, Canada.
NYSE ended the session with Cenovus Energy rising 0.92% to $18.61 on Thursday, following the last session’s upward trend. NYSE jumped 0.05% to $15,436.30, following the last session’s upward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Cenovus Energy has a trailing twelve months EPS of $-1.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.16%.
More news about Cenovus Energy.
4. POSCO (PKX) – Premarket: 2.03%
POSCO Holdings Inc., together with its subsidiaries, manufactures and sells steel rolled products and plates in South Korea and internationally. It operates through four segments: Steel, Construction, Trading, and Others. The company offers hot and cold rolled steel, steel plates, wire rods, galvanized sheets, electrical steel, stainless steel, and titanium. It also engages in the design, manufacture, and construction of steel mills and their facilities, and commercial and residential facilities; export and import of raw materials, as well as provision of supply and purchase transactions between domestic and foreign companies, and various steel products; power generation activities; and provision of network, system integration, and logistics services. In addition, the company is involved in the engineering and construction; research and consulting; architectural design and supervision; investment in venture, energy, and technology industries; electronic commerce; intellectual property services and consulting; transporting and warehousing; real estate development, rental, sale, and management; and education and real estate business. Further, it engages in the resource development; mine development; business facility maintenance; fuel cell; iron ore and coal sales; anode reproduction; and cargo handling business, as well as operates housing business agency. Additionally, the company is involved in the IT service and DVR; electric control engineering; forest resources development; refractory materials sales and furnace maintenance; quicklime manufacturing and sales; wastewater treatment operation and maintenance; rice processing; grain sales; and social enterprise businesses. POSCO Holdings Inc. was incorporated in 1968 and is headquartered in Pohang, South Korea.
NYSE ended the session with POSCO jumping 2.61% to $62.58 on Thursday, after two successive sessions in a row of gains. NYSE rose 0.05% to $15,436.30, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, POSCO has a trailing twelve months EPS of $4.5.
PE Ratio
POSCO has a trailing twelve months price to earnings ratio of 13.92. Meaning, the purchaser of the share is investing $13.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.41%.
Volume
Today’s last reported volume for POSCO is 250771 which is 29.37% above its average volume of 193830.
Moving Average
POSCO’s value is higher than its 50-day moving average of $59.31 and way higher than its 200-day moving average of $50.75.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.5%, now sitting on 86.84T for the twelve trailing months.
More news about POSCO.
5. MicroVision (MVIS) – Premarket: 1.69%
MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. Further, the company develops 1st generation long range lidar. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.
NASDAQ ended the session with MicroVision falling 8.01% to $2.36 on Thursday while NASDAQ slid 0.66% to $11,379.48.
Earnings Per Share
As for profitability, MicroVision has a trailing twelve months EPS of $-0.102.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.24%.
Yearly Top and Bottom Value
MicroVision’s stock is valued at $2.36 at 07:34 EST, way under its 52-week high of $5.96 and way higher than its 52-week low of $2.11.
More news about MicroVision.
6. Gevo (GEVO) – Premarket: 1.63%
Gevo, Inc. operates as a renewable fuels company. It operates through four segments: Gevo, Agri-Energy, Renewable Natural Gas, and Net-Zero. The company commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. Its products also include renewable gasoline and diesel, isooctane, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. Gevo, Inc. has a strategic alliance with Axens North America, Inc. for ethanol-to-jet technology and sustainable aviation fuel commercial project development. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.
NASDAQ ended the session with Gevo falling 0.54% to $1.84 on Thursday while NASDAQ fell 0.66% to $11,379.48.
Earnings Per Share
As for profitability, Gevo has a trailing twelve months EPS of $-0.706.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.05%.
Volatility
Gevo’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.47%, a negative 1.28%, and a positive 3.31%.
Gevo’s highest amplitude of average volatility was 1.47% (last week), 2.81% (last month), and 3.31% (last quarter).
Volume
Today’s last reported volume for Gevo is 5040020 which is 22% below its average volume of 6462170.
Yearly Top and Bottom Value
Gevo’s stock is valued at $1.84 at 07:34 EST, way under its 52-week high of $5.49 and way higher than its 52-week low of $1.65.
More news about Gevo.
7. Toronto Dominion Bank (TD) – Premarket: 1.05%
The Toronto-Dominion Bank, together with its subsidiaries, provides various financial products and services in Canada, the United States, and internationally. It operates through Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, and Wholesale Banking segments. The company offers personal deposits, such as checking, savings, and investment products; financing, investment, cash management, international trade, and day-to-day banking services to businesses; and financing options to customers at point of sale for automotive and recreational vehicle purchases. It also provides credit cards and payments; real estate secured lending, auto finance, and consumer lending services; point-of-sale payment solutions for large and small businesses; wealth and asset management products, and advice to retail and institutional clients through direct investing, advice-based, and asset management businesses; property and casualty insurance; and life and health insurance products, as well as reinsurance products. The company also provides capital markets, and corporate and investment banking products and services, including underwriting and distribution of new debt and equity issues; advice on strategic acquisitions and divestitures; and trading, funding, and investment services to corporations, governments, and institutions. It offers its products and services under the TD Bank and America's Most Convenient Bank brand names. The company operates through a network of 1,060 branches and 3,401 automated teller machines (ATMs) in Canada, and 1,160 stores and 2,693 ATMs in the United States, as well as offers telephone, digital, and mobile banking services. The Toronto-Dominion Bank was founded in 1855 and is headquartered in Toronto, Canada.
NYSE ended the session with Toronto Dominion Bank rising 0.11% to $66.62 on Thursday, after two sequential sessions in a row of gains. NYSE rose 0.05% to $15,436.30, following the last session’s upward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Toronto Dominion Bank has a trailing twelve months EPS of $5.37.
PE Ratio
Toronto Dominion Bank has a trailing twelve months price to earnings ratio of 12.42. Meaning, the purchaser of the share is investing $12.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.5%.
More news about Toronto Dominion Bank.
8. Flex (FLEX) – Premarket: 0.92%
Flex Ltd. provides design, engineering, manufacturing, and supply chain services and solutions to original equipment manufacturers in Asia, the Americas, and Europe. It operates through three segments: Flex Agility Solutions (FAS), Flex Reliability Solutions (FRS), and Nextracker. The company provides cross-industry technologies, including human-machine interface, internet of things platforms, power, sensor fusion, and smart audio. It also offers integrated solar tracker and software solutions used in utility-scale and ground-mounted distributed generation solar projects. In addition, the company provides value-added design and engineering services; and systems assembly and manufacturing services that include enclosures, testing services, and materials procurement and inventory management services. Further, it offers chargers for smartphones and tablets; adapters for notebooks and gaming systems; power supplies for the server, storage, and networking markets; and power solutions, such as switchgear, busway, power distribution, modular power systems, and monitoring solutions and services. Additionally, the company provides after-market and forward supply chain logistics services to computing, consumer digital, infrastructure, industrial, mobile, automotive, and medical industries; and reverse logistics and repair solutions, including returns management, exchange programs, complex repair, asset recovery, recycling, and e-waste management. It serves to cloud, communications, enterprise, automotive, industrial, consumer devices, lifestyle, healthcare, and energy industries. The company was formerly known as Flextronics International Ltd. and changed its name to Flex Ltd. in September 2016. Flex Ltd. was incorporated in 1990 and is based in Singapore.
NASDAQ ended the session with Flex rising 0.07% to $22.77 on Thursday, following the last session’s upward trend. NASDAQ dropped 0.66% to $11,379.48, after four consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.
Earnings Per Share
As for profitability, Flex has a trailing twelve months EPS of $0.83.
PE Ratio
Flex has a trailing twelve months price to earnings ratio of 27.41. Meaning, the purchaser of the share is investing $27.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.37%.
Yearly Top and Bottom Value
Flex’s stock is valued at $22.77 at 07:34 EST, below its 52-week high of $25.12 and way above its 52-week low of $13.63.
Moving Average
Flex’s worth is below its 50-day moving average of $23.16 and way above its 200-day moving average of $18.95.
More news about Flex.
9. Inovio Pharmaceuticals (INO) – Premarket: 0.81%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals sliding 1.48% to $1.24 on Thursday while NASDAQ dropped 0.66% to $11,379.48.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.99%.
Volume
Today’s last reported volume for Inovio Pharmaceuticals is 5165420 which is 8.05% above its average volume of 4780450.
Revenue Growth
Year-on-year quarterly revenue growth grew by 187.5%, now sitting on 2.11M for the twelve trailing months.
More news about Inovio Pharmaceuticals.
10. Tyson Foods (TSN) – Premarket: 0.59%
Tyson Foods, Inc., together with its subsidiaries, operates as a food company worldwide. It operates through four segments: Beef, Pork, Chicken, and Prepared Foods. The company processes live fed cattle and live market hogs; fabricates dressed beef and pork carcasses into primal and sub-primal meat cuts, as well as case ready beef and pork, and fully cooked meats; raises and processes chickens into fresh, frozen, and value-added chicken products, including breaded chicken strips, nuggets, patties, and other ready-to-fix or fully cooked chicken parts; and supplies poultry breeding stock. It also manufactures and markets frozen and refrigerated food products, including ready-to-eat sandwiches, flame-grilled hamburgers, Philly steaks, pepperoni, bacon, breakfast sausage, turkey, lunchmeat, hot dogs, flour and corn tortilla products, appetizers, snacks, prepared meals, ethnic foods, side dishes, meat dishes, breadsticks, and processed meats under the Jimmy Dean, Hillshire Farm, Ball Park, Wright, State Fair, Aidells, and Gallo Salame brands. In addition, the company offers its products under the Tyson and ibp brands. It sells its products through its sales staff to grocery retailers, grocery wholesalers, meat distributors, warehouse club stores, military commissaries, industrial food processing companies, chain restaurants or their distributors, live markets, international export companies, and domestic distributors who serve restaurants and food service operations, such as plant and school cafeterias, convenience stores, hospitals, and other vendors, as well as through independent brokers and trading companies. The company was founded in 1935 and is headquartered in Springdale, Arkansas.
NYSE ended the session with Tyson Foods rising 0.08% to $59.29 on Thursday while NYSE jumped 0.05% to $15,436.30.
Earnings Per Share
As for profitability, Tyson Foods has a trailing twelve months EPS of $5.54.
PE Ratio
Tyson Foods has a trailing twelve months price to earnings ratio of 10.7. Meaning, the purchaser of the share is investing $10.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.75%.
More news about Tyson Foods.
Premarket Losers Today
1. VerifyMe (VRME) – Premarket: -4.62%
VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners the ability to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, authentication, serialization, and track and trace features for labels, packaging, and products. This segment also offers consumer engagement capabilities, custom printing of tamper evident labels, utilizing visible and invisible variable codes, and images printed with its proprietary inks. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Rochester, New York.
NASDAQ ended the session with VerifyMe falling 2.26% to $1.73 on Thursday, following the last session’s downward trend. NASDAQ dropped 0.66% to $11,379.48, after four sequential sessions in a row of losses, on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, VerifyMe has a trailing twelve months EPS of $-1.483.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.7%.
Yearly Top and Bottom Value
VerifyMe’s stock is valued at $1.73 at 07:34 EST, way below its 52-week high of $3.59 and way above its 52-week low of $1.01.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1638.3%, now sitting on 10.13M for the twelve trailing months.
More news about VerifyMe.
2. Plug Power (PLUG) – Premarket: -3.17%
Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including green hydrogen production, storage and delivery, and energy generation through mobile or stationary applications. The company provides proton exchange membrane (PEM), fuel cell and fuel processing technologies, and fuel cell/battery hybrid technologies, as well as related hydrogen and green hydrogen generation, storage, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled PEM fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; and GenFuel Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. It has strategic agreements with Airbus; Lhyfe; Edison Motors; Phillips 66; Apex Clean Energy; BAE Systems; and Universal Hydrogen Co. The company was founded in 1997 and is headquartered in Latham, New York.
NASDAQ ended the session with Plug Power falling 4.44% to $14.21 on Thursday while NASDAQ fell 0.66% to $11,379.48.
Plug Power (plug) reports Q4 earnings: what key metrics have to sayFor the quarter ended December 2022, Plug Power (PLUG Quick QuotePLUG – Free Report) reported revenue of $220.74 million, up 36.3% over the same period last year. , Here is how Plug Power performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Plug Power has a trailing twelve months EPS of $-1.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.53%.
Yearly Top and Bottom Value
Plug Power’s stock is valued at $14.21 at 07:34 EST, way below its 52-week high of $32.05 and way higher than its 52-week low of $11.49.
Sales Growth
Plug Power’s sales growth is 74.7% for the present quarter and 69.3% for the next.
Previous days news about Plug Power
- Plug Power (plug) reports Q4 loss, lags revenue estimates. According to Zacks on Wednesday, 1 March, "While Plug Power has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about Plug Power.
3. Credit Suisse Group (CS) – Premarket: -3%
Credit Suisse Group AG, together with its subsidiaries, provides various financial services in Switzerland, Europe, the Middle East, Africa, the Americas, and Asia Pacific. The company offers wealth management solutions, including investment advice and discretionary asset management services; risk management solutions, such as managed investment products; and wealth planning, succession planning, and trust services. It also provides financing and lending solutions, including consumer credit and real estate mortgage lending, real asset lending relating to ship, and aviation financing for UHNWI; standard and structured hedging, and lombard lending solutions, as well as collateral trading services; and investment banking solutions, such as global securities sales, trading and execution, capital raising, and advisory services. In addition, the company offers banking solutions, such as payments, accounts, debit and credit cards, and product bundles; asset management products; equity and debt underwriting, and advisory services; cash equities, equity derivatives, and convertibles, as well as prime services; and fixed income products, such as credit, securitized, macro, emerging markets, financing, structured credit, and other products. Further, it provides HOLT, a framework for assessing the performance of approximately 20,000 companies; and equity and fixed income research services. The company serves private and institutional clients; ultra-high-net-worth individuals, high-net-worth individuals, and affluent and retail clients; corporate clients, small and medium-sized enterprises, external asset managers, financial institutions, and commodity traders; and pension funds, hedge funds, governments, foundations and endowments, corporations, entrepreneurs, private individuals, financial sponsors, and sovereign clients. As of December 31, 2021, it operated through a network of 311 offices and branches. The company was founded in 1856 and is based in Zurich, Switzerland.
NYSE ended the session with Credit Suisse Group sliding 2.28% to $3.00 on Thursday, after two consecutive sessions in a row of losses. NYSE jumped 0.05% to $15,436.30, following the last session’s upward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Credit Suisse Group has a trailing twelve months EPS of $0.49.
PE Ratio
Credit Suisse Group has a trailing twelve months price to earnings ratio of 6.12. Meaning, the purchaser of the share is investing $6.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.09%.
Volume
Today’s last reported volume for Credit Suisse Group is 15173000 which is 32.77% below its average volume of 22570500.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Credit Suisse Group’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth declined by 32.6%, now sitting on 16.09B for the twelve trailing months.
Moving Average
Credit Suisse Group’s value is under its 50-day moving average of $3.28 and way under its 200-day moving average of $4.69.
More news about Credit Suisse Group.
4. Shinhan Financial Group (SHG) – Premarket: -2.45%
Shinhan Financial Group Co., Ltd. provides financial products and services in South Korea and internationally. The company operates through six segments: Banking, Credit Card, Securities, Life Insurance, Credit, and Others. It offers retail banking services, including demand, savings, and fixed deposit-taking; checking accounts; mortgage and home equity, and retail lending; electronic banking and automatic teller machines (ATM); and bill paying, payroll and check-cashing, currency exchange, and wire fund transfer services. The company also provides corporate banking services, such as investment banking, real estate financing, overseas real estate and development project financing, infrastructure and structured financing, equity/venture investments, mergers and acquisitions consulting; securitization and derivatives services comprising securities and derivative products, and foreign exchange trading; and working capital loans and facilities loans. In addition, it is involved in treasury and investment activities in international capital markets consisting of foreign currency-denominated securities trading, foreign exchange trading and services, trade-related financial services, international factoring services, and foreign banking operations. Further, the company offers trust account management, securities brokerage, and asset management services, as well as leasing and equipment financing, savings banking, loan collection and credit reporting, collective investment administration, private equity investment, and financial system development services. As of December 31, 2021, it operated a network of 784 service centers; 5,234 ATMs; 7 cash dispensers; and 85 digital kiosks. Shinhan Financial Group Co., Ltd. was founded in 1982 and is headquartered in Seoul, South Korea.
NYSE ended the session with Shinhan Financial Group jumping 1.61% to $29.74 on Thursday, after four consecutive sessions in a row of gains. NYSE jumped 0.05% to $15,436.30, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Shinhan Financial Group has a trailing twelve months EPS of $5.93.
PE Ratio
Shinhan Financial Group has a trailing twelve months price to earnings ratio of 5.01. Meaning, the purchaser of the share is investing $5.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.68%.
More news about Shinhan Financial Group.
5. Banco Santander Brasil (BSBR) – Premarket: -2.03%
Banco Santander (Brasil) S.A., together with its subsidiaries, provides various banking products and services to individuals, small and medium enterprises, and corporate customers in Brazil and internationally. The company operates in two segments, Commercial Banking and Global Wholesale Banking. It offers deposits and other bank funding instruments; debit and credit cards; digital prepaid solutions; payment platform; loyalty programs; employee benefit vouchers; payroll loans; digital lending and online debt renegotiation services; mortgages; home equity financing products; consumer credit; and local loans, commercial and trade finance, guarantees, structured loans, and cash management and funding solutions, as well as on-lending transfer services. It also provides funding and financial advisory services related to projects, origination and distribution of fixed-income securities in the debt capital markets, financing of acquisitions and syndicated loans, other structured financing arrangements, and subordinated debt and energy efficiency transactions; advisory services for mergers and acquisitions, and equity capital markets transactions; and stock brokerage and advisory, equity, and equity research services. In addition, the company structures and offers foreign exchange, derivative, and investment products for institutional investors, and corporate and retail customers; and provides market making services. Further, it offers instant payment services; range of products and services focused on the agribusiness sector; microfinance services; and online automotive listing and digital car insurance solutions, as well as digital trading platform. Additionally, it provides its financial services and products to its customers through multichannel distribution network comprising branches, mini-branches, ATMs, call centers, Internet banking, and mobile banking. Banco Santander (Brasil) S.A. was incorporated in 1985 and is headquartered in São Paulo, Brazil.
NYSE ended the session with Banco Santander Brasil sliding 0.55% to $5.43 on Thursday while NYSE jumped 0.05% to $15,436.30.
Earnings Per Share
As for profitability, Banco Santander Brasil has a trailing twelve months EPS of $0.67.
PE Ratio
Banco Santander Brasil has a trailing twelve months price to earnings ratio of 8.1. Meaning, the purchaser of the share is investing $8.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.6%.
Moving Average
Banco Santander Brasil’s value is below its 50-day moving average of $5.49 and below its 200-day moving average of $5.70.
Sales Growth
Banco Santander Brasil’s sales growth is negative 8% for the current quarter and negative 3.3% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Banco Santander Brasil’s stock is considered to be overbought (>=80).
More news about Banco Santander Brasil.
6. Lloyds Banking Group (LYG) – Premarket: -2%
Lloyds Banking Group plc, together with its subsidiaries, provides a range of banking and financial services in the United Kingdom. It operates through three segments: Retail; Commercial Banking; and Insurance and Wealth. The Retail segment offers a range of financial service products, including current accounts, savings, mortgages, motor finance, unsecured loans, leasing solutions, and credit cards to personal and small business customers. The Commercial Banking segment provides lending, transactional banking, working capital management, risk management, debt financing, and debt capital market services to small and medium-sized entities, corporates, and financial institutions. The Insurance and Wealth segment offers insurance, investment and wealth management products and services. It also provides digital banking services. The company offers its products and services under the Lloyds Bank, Halifax, Bank of Scotland, and Scottish Widows brands. Lloyds Banking Group plc was founded in 1695 and is based in London, the United Kingdom.
NYSE ended the session with Lloyds Banking Group sliding 1.19% to $2.50 on Thursday while NYSE rose 0.05% to $15,436.30.
Earnings Per Share
As for profitability, Lloyds Banking Group has a trailing twelve months EPS of $0.0003.
PE Ratio
Lloyds Banking Group has a trailing twelve months price to earnings ratio of 7575.45. Meaning, the purchaser of the share is investing $7575.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9%.
Volatility
Lloyds Banking Group’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.44%, a negative 0.42%, and a positive 1.42%.
Lloyds Banking Group’s highest amplitude of average volatility was 2.46% (last week), 1.47% (last month), and 1.42% (last quarter).
Volume
Today’s last reported volume for Lloyds Banking Group is 7246890 which is 2.67% above its average volume of 7058290.
More news about Lloyds Banking Group.
7. Xenetic Biosciences (XBIO) – Premarket: -1.96%
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
NASDAQ ended the session with Xenetic Biosciences falling 1.92% to $0.51 on Thursday while NASDAQ slid 0.66% to $11,379.48.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be overbought (>=80).
More news about Xenetic Biosciences.
8. Prudential Public Limited Company (PUK) – Premarket: -1.8%
Prudential plc, through its subsidiaries, provides life and health insurance, and retirement and asset management solutions to individuals in Asia, and Africa. It offers health and protection, as well as savings products, such as participating, linked, and other traditional products. The company also provides insurance against common critical illnesses, including cancer, stroke, and heart attack; and tropical disease protection, such as dengue, malaria, and measles. It manages assets across equity, fixed income, multi asset, quantitative, and alternative strategies on behalf of institutional and individual investors. Prudential plc provides its products and services through agency sales force, banks, and brokers. The company was founded in 1848 and is headquartered in London, the United Kingdom.
NYSE ended the session with Prudential Public Limited Company jumping 1.42% to $31.07 on Thursday, after five successive sessions in a row of gains. NYSE jumped 0.05% to $15,436.30, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Prudential Public Limited Company has a trailing twelve months EPS of $1.63.
PE Ratio
Prudential Public Limited Company has a trailing twelve months price to earnings ratio of 19.03. Meaning, the purchaser of the share is investing $19.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.69%.
Moving Average
Prudential Public Limited Company’s value is above its 50-day moving average of $29.95 and way higher than its 200-day moving average of $24.71.
Yearly Top and Bottom Value
Prudential Public Limited Company’s stock is valued at $31.07 at 07:34 EST, below its 52-week high of $34.37 and way higher than its 52-week low of $18.20.
More news about Prudential Public Limited Company.
9. Merrimack Pharmaceuticals (MACK) – Premarket: -1.79%
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
NASDAQ ended the session with Merrimack Pharmaceuticals jumping 2.09% to $11.72 on Thursday while NASDAQ fell 0.66% to $11,379.48.
Earnings Per Share
As for profitability, Merrimack Pharmaceuticals has a trailing twelve months EPS of $-0.23.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.98%.
Yearly Top and Bottom Value
Merrimack Pharmaceuticals’s stock is valued at $11.72 at 07:34 EST, way under its 52-week high of $13.66 and way higher than its 52-week low of $3.00.
More news about Merrimack Pharmaceuticals.
10. DouYu (DOYU) – Premarket: -1.56%
DouYu International Holdings Limited, together with its subsidiaries, operates a platform on PC and mobile apps that provides interactive games and entertainment live streaming services in the People's Republic of China. Its platform connects game developers and publishers, professional eSports teams or players and eSports tournament organizers, advertisers, and viewers. The company also sponsors eSports teams and organizes eSports tournaments. In addition, it streams other content to include a spectrum of live streaming entertainment options, such as talent shows, music, outdoor, and travel. Further, the company records and offers video clips to allow users to watch replays of selective live streaming content; and allows viewers and streamers to edit and upload short video clips by themselves. DouYu International Holdings Limited was founded in 2014 and is headquartered in Wuhan, the People's Republic of China.
NASDAQ ended the session with DouYu rising 2.4% to $1.28 on Thursday while NASDAQ dropped 0.66% to $11,379.48.
Earnings Per Share
As for profitability, DouYu has a trailing twelve months EPS of $-0.255.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.93%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 23.4%, now sitting on 7.76B for the twelve trailing months.
Sales Growth
DouYu’s sales growth is negative 19.7% for the present quarter and 2.9% for the next.
Yearly Top and Bottom Value
DouYu’s stock is valued at $1.28 at 07:34 EST, way under its 52-week high of $2.48 and way above its 52-week low of $0.90.
More news about DouYu.
Stay up to date with our premarket winners and losers daily report
